Sofosvel – A Project of Reinforcelab
Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment manufactured by Beacon Pharmaceuticals Limited. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated).
We have ensured best quality design for the website to make it user friendly for the customers. We have also set several call action to increase the sales rate of the product’s website.